Midodrin Evolan (Midodrine Hydrochloride)

Midodrine is a pro‑drug that is converted in the body to desglymidodrine. The active metabolite selectively activates peripheral alpha‑1 adrenergic receptors, causing blood‑vessel constriction. This raises systemic vascular resistance and improves blood pressure when a patient moves to an upright position.

The appropriate dose of Midodrin Evolan is determined by the prescribing clinician based on the individual’s condition, response, and tolerability. Dosage adjustments are made according to blood‑pressure measurements and clinical judgment.

The pregnancy safety category for midodrine hydrochloride is unknown. It should only be used during pregnancy or lactation if the potential benefit outweighs any possible risk to the fetus or infant, and after a careful risk‑benefit assessment by the healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Midodrine is an oral alpha‑1 agonist that directly increases vascular tone, whereas alternatives such as fludrocortisone act by expanding plasma volume. Midodrine typically has a faster onset and is useful when rapid blood‑pressure support is needed, but it may cause supine hypertension, a consideration not shared by all other agents.

Midodrin Evolan should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Midodrin Evolan is taken orally, usually with a full glass of water. The tablet is swallowed whole and not chewed or crushed. Dosing times are typically spaced throughout the day, and the last dose is often taken several hours before bedtime to reduce the risk of supine hypertension.

The most serious risks include severe supine hypertension, which can lead to cardiovascular complications, and rare but serious events such as bradycardia, arrhythmias, or peripheral ischemia. Patients should be monitored closely for any signs of excessive blood‑pressure elevation, especially when lying down.

Midodrin Evolan is contraindicated in patients with severe organic heart disease, uncontrolled hypertension, or known hypersensitivity to midodrine or any of its excipients. It should also be avoided in individuals who cannot safely monitor their blood pressure while on therapy.